Published in Hepatitis Weekly, March 14th, 2005
SciGen's entry into the European market has been made possible as a consequence of SciGen acquiring worldwide rights to Sci-B-Vac, its third generation hepatitis B vaccine.
The Commercialization Agreement between SciGen and Berna comprehends annual minimum orders by Berna over an initial 5-year term generating significant revenues for the company. The agreement provides for automatic renewals, with a 1-year notice...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.